DMP-2/500
Description
- Triple combination for effective type 2 diabetes management
- Glimepiride 2 mg: Stimulates insulin secretion from pancreatic beta cells
- Pioglitazone 15 mg: Enhances insulin sensitivity in muscle and adipose tissue
- Metformin ER 500 mg: Reduces hepatic glucose output and improves insulin action
- Extended-release formula: Sustained glucose control and reduced GI side effects
- Helps manage both fasting and post-meal blood sugar levels
- Suitable for patients needing intensive glycemic control
- Reduces the risk of microvascular and macrovascular complications
Composition
Glimepiride 2 mg + Pioglitazone 15 mg + Metformin (Extended Release) 500 mg
Benefits
DMP-2/500 offers a comprehensive approach to managing type 2 diabetes by addressing multiple pathophysiological defects. It effectively lowers both fasting and postprandial blood glucose levels, enhances insulin sensitivity, and reduces insulin resistance. The extended-release formulation of Metformin ensures sustained action with improved gastrointestinal tolerance. This combination therapy supports better HbA1c reduction, reduces the risk of diabetes-related complications, and promotes metabolic stability, making DMP-2/500 an excellent option for patients not adequately controlled with dual therapy or monotherapy.
Introduction
DMP-2/500 is a powerful oral antidiabetic combination that brings together three well-established agents—Glimepiride, Pioglitazone, and Metformin (Extended Release)—to provide optimal glycemic control in patients with type 2 diabetes mellitus. Glimepiride (2 mg), a sulfonylurea, stimulates insulin release from the pancreas. Pioglitazone (15 mg), a thiazolidinedione, improves insulin sensitivity at the cellular level. Metformin (ER) 500 mg reduces hepatic glucose production and enhances peripheral insulin action. This triple therapy is especially beneficial for patients requiring more intensive treatment for better long-term blood sugar regulation.
